Krystal Biotech (KRYS) Depreciation & Amortization (CF) (2019 - 2023)

Krystal Biotech has reported Depreciation & Amortization (CF) for 11 years, with the latest figure at $1.4 million in Q2 2026.

• Depreciation & Amortization (CF) for Q2 2026 came in at $1.4 million, up 7.69% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.8 million (up 8.12% YoY), and the FY2025 annual result was $5.7 million, down 4.6% from the prior year.
• Depreciation & Amortization (CF) slipped to $1.4 million in Q2 2026, from $1.5 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.8 million in Q2 2024 and troughed at $705000.0 in Q1 2023.
• A 5-year average of $1.3 million and a median of $1.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The widest annual swing landed in 2023, when Depreciation & Amortization (CF) slumped 30.54%; it then soared 102.41% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.1 million in 2022, then jumped by 38.38% to $1.5 million in 2023, then declined by 7.3% to $1.4 million in 2024, then increased by 9.09% to $1.5 million in 2025, then slipped by 8.14% to $1.4 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $1.4 million in Q2 2026, $1.5 million in Q1 2026, and $1.5 million in Q4 2025.